Skip to content
DraconiticResearch
Search Sources API
197,693 studies31 sourcesUpdated 25 min ago
Peer-reviewedCC BYFrontiers in oncology

Chemoresistance in cervical cancer: identifying and exploiting non-coding RNAs.

  • Lilian Makgoo1
  • Zukile Mbita1
  1. 1Department of Biochemistry, Microbiology and Biotechnology, University of Limpopo, Polokwane, South Africa.
Read full textPDFDOICite

Abstract

Drug resistance continues to pose a significant challenge, accounting for a large proportion of relapses and playing a major role in cervical cancer-related mortality worldwide. Emerging evidence has indicated that the aberrant expression of non-coding RNAs, especially circular RNAs (circRNAs), long non-coding RNAs (lncRNAs), and microRNAs (miRNAs) is responsible for drug resistance, which poses a significant challenge to the success of chemotherapy. Addressing drug resistance is crucial for improving patient outcomes and reducing the burden of cervical cancer on healthcare systems. In this review, we summarize the molecular and cellular mechanisms through which circRNAs, miRNAs and lncRNAs mediate drug resistance to common drugs used in the treatment of cervical cancer. This work underscores non-coding RNAs as a promising therapeutic target, offering a potential avenue for overcoming chemoresistance in cervical cancer.

Related

  1. Single-cell transcriptome profiling of post-treatment and treatment-naïve colorectal cancer: Insights into putative mechanisms of chemoresistance
    Grigory Puzanov, Clémence Astier, Dimitris Papakonstantinou +9
    Cancer LettersPeer-reviewedCC BY 4.0Full text5 citedProteomics & metabolomicsGeneral biologyHAL
  2. Identifying Determinants of Outcome in Post-Radiotherapy Cervical Carcinoma Requiring Adjuvant Surgery
    Latha Kiran Krishna Rajendran
    International Journal of Clinical Research and Medical SciencesPeer-reviewedCC BYFull text18 citedObstetrics, gynaecology & paediatricsOpenAlex
  3. SRPK1 is a determinant of chemoresistance to Docetaxel in prostate cancer
    D. Duzgun, W. Read, S. Oltean
    bioRxivPreprintCC BYFull textOncologybioRxiv
  4. SENP3 loss in biliary tract cancer chemoresistance: substrate-specific control of fatty acid oxidation and mitophagy
    Wanxu Zheng, Shiji Xia, Wangdong Zhu +1
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Pharmacology & toxicologyFrontiersCrossref
  5. The Role of D-3-Phosphoglycerate Dehydrogenase (PHGDH) in Chemoresistance in Ovarian Cancer: Molecular Insights and Therapeutic Potential
    Jesús Omar Velázquez-Moreno, María de la Luz Mejía-Aguayo, Felix De Dios Padre Casarrubias-Jaimes +7
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0OncologyCrossref

Cite

BibTeXRIS
BibTeX
@article{makgoo2026chemoresistance,
  title = {{Chemoresistance in cervical cancer: identifying and exploiting non-coding RNAs.}},
  author = {Lilian Makgoo and Zukile Mbita},
  journal = {Frontiers in oncology},
  year = {2026},
  month = oct,
  doi = {10.3389/fonc.2026.1913768},
  url = {https://europepmc.org/article/MED/42903611},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Chemoresistance in cervical cancer: identifying and exploiting non-coding RNAs.
AU  - Lilian Makgoo
AU  - Zukile Mbita
PY  - 2026
DA  - 2026/10/06
JO  - Frontiers in oncology
DO  - 10.3389/fonc.2026.1913768
UR  - https://europepmc.org/article/MED/42903611
AB  - Drug resistance continues to pose a significant challenge, accounting for a large proportion of relapses and playing a major role in cervical cancer-related mortality worldwide. Emerging evidence has indicated that the aberrant expression of non-coding RNAs, especially circular RNAs (circRNAs), long non-coding RNAs (lncRNAs), and microRNAs (miRNAs) is responsible for drug resistance, which poses a significant challenge to the success of chemotherapy. Addressing drug resistance is crucial for improving patient outcomes and reducing the burden of cervical cancer on healthcare systems. In this review, we summarize the molecular and cellular mechanisms through which circRNAs, miRNAs and lncRNAs mediate drug resistance to common drugs used in the treatment of cervical cancer. This work underscores non-coding RNAs as a promising therapeutic target, offering a potential avenue for overcoming chemoresistance in cervical cancer.
SN  - 2234-943X
ER  -